GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » EV-to-FCF

CureVac NV (CureVac NV) EV-to-FCF : -0.79 (As of May. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CureVac NV's Enterprise Value is $274.93 Mil. CureVac NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-347.81 Mil. Therefore, CureVac NV's EV-to-FCF for today is -0.79.

The historical rank and industry rank for CureVac NV's EV-to-FCF or its related term are showing as below:

CVAC' s EV-to-FCF Range Over the Past 10 Years
Min: -2309.97   Med: -3.25   Max: -0.36
Current: -0.79

During the past 6 years, the highest EV-to-FCF of CureVac NV was -0.36. The lowest was -2309.97. And the median was -3.25.

CVAC's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 7.545 vs CVAC: -0.79

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), CureVac NV's stock price is $3.10. CureVac NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.274. Therefore, CureVac NV's PE Ratio for today is At Loss.


CureVac NV EV-to-FCF Historical Data

The historical data trend for CureVac NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV EV-to-FCF Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - 22.59 -5.68 -1.72 -1.55

CureVac NV Quarterly Data
Dec18 Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.72 -2.65 -5.22 -3.00 -1.55

Competitive Comparison of CureVac NV's EV-to-FCF

For the Biotechnology subindustry, CureVac NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CureVac NV's EV-to-FCF falls into.



CureVac NV EV-to-FCF Calculation

CureVac NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=274.929/-347.814
=-0.79

CureVac NV's current Enterprise Value is $274.93 Mil.
CureVac NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-347.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV  (NAS:CVAC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CureVac NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.10/-1.274
=At Loss

CureVac NV's share price for today is $3.10.
CureVac NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.274.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CureVac NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CureVac NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (CureVac NV) Business Description

Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.